YU LIU^*, ROBERT J. KASPER, NATALIE J. S. CHOI^*

BIOCELL, Vol.48, No.1, pp. 1-8, 2024, DOI:10.32604/biocell.2023.031158

Abstract Extracellular vesicles (EVs) are membranous vesicular structures released from almost all eukaryotic cell types under different physiological or pathological conditions. Growing evidence demonstrates that EVs can serve as mediators of intercellular communication between donor and recipient cells or microorganism-infected and noninfected cells. Coronavirus disease 2019 (COVID-19) disease is caused by infection of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) of host cells in the respiratory system and various extra-pulmonary tissue/organs, resulting in complications of multiple organ systems. As the cell surface receptor, angiotensin-converting enzyme 2 (ACE2) mediates cellular entry of SARS-CoV-2 into the host cells in patients with COVID-19.… More >

GIULIA CHIABOTTO^1,*, STEFANIA BRUNO^2,*

BIOCELL, Vol.47, No.7, pp. 1499-1508, 2023, DOI:10.32604/biocell.2023.028121

Abstract Renal fibrosis and inflammation are common pathological features of chronic kidney disease (CKD). Since currently available treatments can only delay the progression of CKD, the outcome of patients with CKD is still poor. One therapeutic option for the prevention of CKD-related complications could be the use of mesenchymal stromal cells (MSCs), which have shown beneficial effects in tissue fibrosis and regeneration after damage. However, safety issues, such as cellular rejection and carcinogenicity, limit their clinical application. Among the bioactive factors secreted by MSCs, extracellular vesicles (EVs) have shown the same beneficial effect of MSCs, without any notable side effects. This… More > Graphic Abstract

YANGYI HE^1,2, DAVID SANCHEZ-LORENTE^3,4,5, MELISSA ACOSTA-PLASENCIA¹, MARC BOADA^3,4,5, ANGELA GUIRAO^3,4,5, RAMON M. MARRADES^4,5,6,7, LAUREANO MOLINS^3,4,5, ALFONS NAVARRO^1,4,5,*

BIOCELL, Vol.47, No.5, pp. 951-957, 2023, DOI:10.32604/biocell.2023.027718

Abstract Tumor-secreted extracellular vesicles (EVs) participate in the metastasis process through different mechanisms, including the preparation of the pre-metastatic niche to grant circulating tumor cells (CTCs) implantation and growth. The study of the metastasis process through the analysis of CTCs and tumor-derived EVs is difficult because of the dilution grade of these elements in peripheral blood. In early-stage lung cancer patients, the tumor-secreted products are even more diluted. An attractive strategy in surgical lung cancer patients is to purify them from a pulmonary tumor-draining vein where they are enriched. The information obtained from the analysis of EVs and CTCs purified from… More >

MOHADESEH NEMATI¹, YOUSEF RASMI¹, JAFAR REZAIE^2,*

BIOCELL, Vol.47, No.3, pp. 455-464, 2023, DOI:10.32604/biocell.2023.025603

Abstract Colorectal cancer (CRC) is the third most common cancer and the leading cause of cancer death globally. Resistance to therapy is a challenge for CRC treatment. Mesenchymal stem cells (MSCs) have become one of the furthermost effective approaches for tumor treatment due to their specific feature; however, their therapeutic function is controversial. Recently, extracellular vesicles (EVs) derived from MSCs (MSCs-EVs) have attracted extensive research attention due to their promising role in CRC treatment. EVs are cell-derived vesicles that transfer different biomolecules between cells, contributing to intracellular communication. MSCs-EVs can suppress CRC by delivering therapeutic agents to tumor cells. Several studies… More >

W. BENTON SWANSON, YUJI MISHINA^*

BIOCELL, Vol.46, No.6, pp. 1445-1451, 2022, DOI:10.32604/biocell.2022.018781

Abstract Mesenchymal stem cells (MSCs) have long been regarded as critical components of regenerative medicine strategies, given their multipotency and persistence in a variety of tissues. Recently, the specific role of MSCs in mediating regenerative outcomes has been attributed (in part) to secreted factors from transplanted cells, namely extracellular vesicles. This viewpoint manuscript highlights the promise of cell-derived extracellular vesicles as agents of regeneration, enhanced by synergy with appropriate biomaterials platforms. Extracellular vesicles are a potentially interesting regenerative tool to enhance the synergy between MSCs and biomaterials. As a result, we believe these technologies will improve patient outcomes through efficient therapeutic… More >

YASHVI SHARMA¹, SHARDA RAY², SUJATA MOHANTY^1,*

BIOCELL, Vol.46, No.6, pp. 1435-1438, 2022, DOI:10.32604/biocell.2022.018612

Abstract Neurodegenerative disorders are a vicious woe to the public health and wellness. Uncertainty in their underlying causes, lack of effective biomarkers for their early detection, existence of only supportive therapy, and their ever rising incidence creates an unmatched need for targeted therapies. Mesenchymal Stem Cells (MSCs) have found to be promising candidates for regenerative and remedial therapy in neurodegenerative disorders, however several biological risks and practical issues impede in their translational utility. Deriving from MSCs are certain Extracellular Vesicles (EVs), which aid in the paracrine action of MSCs and have lately gained the scientific interest for their implacability in diverse… More >

KENJI TSUJI^*, SHINJI KITAMURA, JUN WADA

BIOCELL, Vol.46, No.4, pp. 899-902, 2022, DOI:10.32604/biocell.2022.018594

Abstract Mesenchymal stem cells (MSCs) have abilities to mediate tissue protection through mechanisms of anti-apoptosis, anti-oxidative stress and anti-fibrosis as well as tissue regeneration through mechanisms of cell proliferation, differentiation and angiogenesis. These effects by MSCs are mediated by a variety of factors, including growth factors, cytokines and extracellular vesicles (EVs). Among these factors, EVs, containing proteins, mRNA and microRNAs (miRNA), may carry their contents into distant tissues with high stability. Therefore, the treatment with MSC-derived EVs may be promising as ‘natural’ drug delivery systems (DDS). Especially, the treatment of MSC-derived EVs with the manipulation of specific miRNAs expression has been… More >

THAÍS CASAGRANDE PAIM, MÁRCIA ROSÂNGELA WINK^*

BIOCELL, Vol.46, No.4, pp. 913-922, 2022, DOI:10.32604/biocell.2022.018498

Abstract Mesenchymal stem cells (MSCs) play key roles in regenerative medicine by promoting tissue healing. MSCs can be isolated from different adult tissues and they are able to differentiate into several lineages. Due to their anti-inflammatory, angiogenic and immune-modulatory properties, MSCs are suitable for tissue engineering applications and, when associated with biomaterials, their benefits can be improved. Moreover, recently, MSCs have been studied for new clinical applications, such as in the treatment of patients with COVID-19. MSCs regenerative potential has been attributed to their secretome, which comprises extracellular matrix, soluble proteins and several elements, including the release of extracellular vesicles. Even… More >

ODIN RAMIREZ-FERNANDEZ^1,2, ESMERALDA ZUÑIGA-AGUILAR^3,*

BIOCELL, Vol.46, No.2, pp. 325-338, 2022, DOI:10.32604/biocell.2022.016892

Abstract This review aims to offer a vision of the clinical reality of cell therapy today in intensive medicine. For this, it has been carried out a description of the properties, functions, and Mesenchymal Stem Cells (MSCS) sources to subsequently address the evidence in preclinical models and studies clinical trials with whole cells and models attributed to small extracellular vesicles (sEVs), nanoparticles made up of microvesicles secreted by cells with an effect on the extracellular matrix, and their impact as an alternative towards cell-free regenerative medicine. MSCs are cells that enhance the regenerative capacity which can be differentiated typically in different… More >